Aastrom Biosciences, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
13. August 2013 09:59 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Aug. 13, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences Announces Amendment of Series B Preferred Stock Certificate of Designations, Preferences and Rights
12. August 2013 14:29 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Aug. 12, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences Reports Second-Quarter and First-Half 2013 Financial Results
07. August 2013 16:05 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., Aug. 7, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences to Present at the JMP Securities Healthcare Conference
03. Juli 2013 09:00 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., July 3, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
Aastrom Biosciences Reports First Quarter 2013 Financial Results
08. Mai 2013 16:00 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., May 8, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...
Aastrom to Host First Quarter 2013 Investor Call on May 8, 2013
03. Mai 2013 16:00 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., May 3, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe,...
Aastrom to Hold Annual Meeting of Shareholders on May 2, 2013
25. April 2013 16:30 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., April 25, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences Announces First Patients Treated in ixCELL-DCM Clinical Study of ixmyelocel-T
19. April 2013 09:00 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., April 19, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences to Present at Multiple Conferences in April
09. April 2013 16:12 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., April 9, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe,...
Aastrom Biosciences Announces First Patients Enrolled in ixCELL-DCM Phase 2b Clinical Trial of Ixmyelocel-T
04. April 2013 09:00 ET
|
Aastrom Biosciences, Inc.
ANN ARBOR, Mich., April 4, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe...